Industry
Drug Manufacturers - Specialty & Generic
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Loading...
Open
2.06
Mkt cap
139M
Volume
626K
High
2.14
P/E Ratio
-6.42
52-wk high
3.12
Low
1.95
Div yield
N/A
52-wk low
0.72
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:32 am
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 10:41 am
Portfolio Pulse from Henry Khederian
October 09, 2024 | 2:41 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 12:57 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 12:03 pm
Portfolio Pulse from Avi Kapoor
October 09, 2024 | 6:49 am
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 8:10 pm
Portfolio Pulse from Benzinga Newsdesk
October 08, 2024 | 8:03 pm
Portfolio Pulse from Benzinga Newsdesk
September 24, 2024 | 11:32 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:33 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.